Dravet 症候群市場規模、佔有率、成長分析（按發作類型、按診斷、按嚴重程度、按治療、按最終用戶、按分銷管道、按地區）- 行業預測 2025-2032

2023 年，Dravet 症候群市場規模價值為 3.7617 億美元，預計將從 2024 年的 4.1153 億美元成長到 2032 年的 8.4438 億美元，預測期內（2025-2032 年）的複合年成長率為 9.4%。

Dravet 症候群是一種罕見的慢性癲癇症，主要影響出生後第一年的嬰兒，並且常常由發燒引起。這種嚴重的神經系統疾病由於反覆發作，給管理和護理帶來了重大挑戰。隨著 Dravet 病情的進展，患者面臨各種併發症，凸顯了對專業醫療照護和對患者及其家人持續支持的必要性。該疾病的複雜性和特殊性凸顯了有針對性的干涉和資源的重要性，推動了市場對創新治療和全面護理解決方案的需求。開發 Dravet 症候群治療方法和支持系統的公司有很大機會滿足這個弱勢患者群體的需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

Dravet 症候群市場規模（依癲癇發作類型和複合年成長率） (2025-2032)

• 市場概覽
• 肌陣攣性癲癇
• 猝倒症
• 局部性癲癇
• 強直陣攣性發作
• 光敏性癲癇
• 其他

Dravet 症候群市場規模（按診斷和複合年成長率） (2025-2032)

• 市場概覽
• MRI
• 心電圖
• SCN1A檢測

Dravet 症候群市場規模（依嚴重程度及複合年成長率） （2025-2032 年）

• 市場概覽
• 溫和的
• 緩和
• 嚴格的

Dravet 症候群市場規模：依治療方法及複合年成長率（2025-2032）

• 市場概覽
• 癲癇
• 藥品
• Clobazam
• 司替戊醇
• 丙戊酸鈉
• 生酮飲食
• 迷走神經刺激
• 其他

Dravet 症候群市場規模（依最終使用者和複合年成長率）(2025-2032)

• 市場概覽
• 製藥公司
• 醫院
• 診斷
• 研究所
• 學術研究所
• 其他

德拉維特症候群市場規模（依分銷管道分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 直接競標
• 醫院藥房
• 零售藥局
• 其他

德拉維特症候群市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Stoke Therapeutics（USA）
• Lundbeck A/S（Denmark）
• Sanofi（France）
• Biocodex SA（France）
• Jazz Pharmaceuticals plc（Ireland）
• Ovid Therapeutics Inc.（USA）
• AbbVie Inc.（USA）
• PTC Therapeutics Inc.（USA）
• Epygenix Therapeutics Inc.（USA）
• Marinus Pharmaceuticals Inc.（USA）
• Neurocrine Biosciences Inc.（USA）
• Aquestive Therapeutics Inc.（USA）
• Eisai Co., Ltd.（Japan）
• Tevard Biosciences GmbH（Germany）
• Anavex Life Sciences Corp.（USA）
• Supernus Pharmaceuticals Inc.（USA）
• Xenon Pharmaceuticals Inc.（Canada）
• Zydus Lifesciences Ltd.（India）
• Sun Pharmaceutical Industries Ltd.（India）
• Lupin Ltd.（India）

結論和建議

Dravet Syndrome Market size was valued at USD 376.17 million in 2023 and is poised to grow from USD 411.53 million in 2024 to USD 844.38 million by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).

Dravet syndrome, a rare and chronic form of epilepsy, primarily manifests in infants during their first year of life, often triggered by fevers. This severe neurological condition leads to recurrent seizures, creating significant challenges for management and care. As Dravet progresses, patients face various complications, highlighting the critical need for specialized medical attention and continuous support for both patients and their families. The complexity and uniqueness of this disorder underscore the importance of targeted interventions and resources, indicating a demand for innovative treatments and comprehensive care solutions in the market. Companies developing therapies and support systems for Dravet syndrome have a significant opportunity to address the needs of this vulnerable patient population.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dravet Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dravet Syndrome Market Segments Analysis

Global Dravet Syndrome Market is segmented by Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel and region. Based on Type of seizures, the market is segmented into Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive seizures and Others. Based on Diagnosis, the market is segmented into MRI, ECG and SCN1A testing. Based on Severity, the market is segmented into Mild, Moderate and Severe. Based on Treatment, the market is segmented into Seizure, Medication, Clobazam, Stiripentol, Sodium Valproate, Ketogenic diet, Vagus Nerve stimulation and Others. Based on End-Use, the market is segmented into Pharma companies, Hospitals, Diagnostic, Laboratories, Academic and Research Institutes and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Hospital pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dravet Syndrome Market

One of the key market drivers for the Global Dravet Syndrome Market is the increasing prevalence of the disorder, which is a severe form of epileptic encephalopathy typically diagnosed in childhood. As awareness of Dravet syndrome grows among healthcare professionals and the general public, there is a rising demand for effective treatment options. The development and approval of innovative therapies, particularly targeted pharmacological agents and advanced treatment modalities such as cannabidiol-based medications, are further propelling market growth. Additionally, ongoing research into the genetic and molecular mechanisms of Dravet syndrome is expected to yield novel therapeutic approaches, enhancing treatment outcomes and fostering market expansion.

Restraints in the Dravet Syndrome Market

The Dravet Syndrome market encounters several restraints that could hinder its anticipated revenue growth. One significant challenge is the persistent societal stigma surrounding epilepsy and related seizure disorders, which leads to discrimination and misinformation in various regions around the world. This stigma often discourages individuals from pursuing treatment, as they may fear the negative perceptions associated with their condition. As a result, the reluctance to seek necessary medical care could adversely impact the market, limiting access to crucial therapies and treatments for those affected by Dravet Syndrome. Addressing these societal barriers will be vital for market progress.

Market Trends of the Dravet Syndrome Market

The Dravet syndrome market is witnessing a significant upswing, driven by recent regulatory advancements that enhance treatment options for this challenging condition. Key approvals, such as those for Stiripentol (Diacomit) and Epidiolex, have notably improved symptom management, showcasing Milestones in therapeutic interventions. The landscape is poised for further growth with the anticipated approval of ZX008 (Fintepla) from Zogenix, reflecting an increasing focus on innovative therapies that address unmet medical needs in the Dravet syndrome community. This convergence of regulatory support and innovative drug development positions the market for rapid expansion, meeting the needs of patients and caregivers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dravet Syndrome Market Size by Type of seizures & CAGR (2025-2032)

• Market Overview
• Myoclonic Seizures
• Atonic Seizures
• Partial Seizures
• Tonic-Clonic Seizures
• Photosensitive seizures
• Others

Global Dravet Syndrome Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• MRI
• ECG
• SCN1A testing

Global Dravet Syndrome Market Size by Severity & CAGR (2025-2032)

• Market Overview
• Mild
• Moderate
• Severe

Global Dravet Syndrome Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Seizure
• Medication
• Clobazam
• Stiripentol
• Sodium Valproate
• Ketogenic diet
• Vagus Nerve stimulation
• Others

Global Dravet Syndrome Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Pharma companies
• Hospitals
• Diagnostic
• Laboratories
• Academic and Research Institutes
• Others

Global Dravet Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tender
• Hospital pharmacy
• Retail Pharmacy
• Others

Global Dravet Syndrome Market Size & CAGR (2025-2032)

• North America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • US
  • Canada
• Europe (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Stoke Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marinus Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tevard Biosciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xenon Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations